Anaphylaxis epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 4: | Line 4: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | |||
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide. | |||
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide. | |||
===Prevalence=== | |||
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide. | |||
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide. | |||
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually. | |||
===Case-fatality rate/Mortality rate=== | |||
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%. | |||
*The case-fatality rate/mortality rate of [disease name] is approximately [number range]. | |||
===Age=== | |||
*Patients of all age groups may develop [disease name]. | |||
*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years. | |||
*[Disease name] commonly affects individuals younger than/older than [number of years] years of age. | |||
*[Chronic disease name] is usually first diagnosed among [age group]. | |||
*[Acute disease name] commonly affects [age group]. | |||
===Race=== | |||
*There is no racial predilection to [disease name]. | |||
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name]. | |||
===Gender=== | |||
*[Disease name] affects men and women equally. | |||
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1. | |||
===Region=== | |||
*The majority of [disease name] cases are reported in [geographical region]. | |||
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2]. | |||
===Developed Countries=== | ===Developed Countries=== | ||
An estimated 1.24% to 16.8% of the population of the United States is considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens, especially [[penicillin]] and insect stings. Most of these people successfully avoid their [[allergen]]s and will never experience anaphylaxis. Of those people who actually experience anaphylaxis, up to 1% may die as a result.<ref>Neugut, Alfred, Anita Ghatak and Rachel Miller. "Anaphylaxis in the United States: An Investigation Into Its Epidemiology." Arch Intern Med. 161.108 January 2001 15-21. 29 January 2007 <http://archinte.ama-assn.org/cgi/content/full/161/1/15>.</ref> Anaphylaxis results in fewer than 1,000 deaths per year in the U.S. (compared to 2.4 million deaths from all causes each year in the U.S.<ref name="urlFASTSTATS - Deaths and Mortality">{{cite web |url=http://www.cdc.gov/nchs/fastats/deaths.htm |title=FASTSTATS - Deaths and Mortality |format= |work= |accessdate=2013-02-13}}</ref>). The most common presentation includes sudden cardiovascular collapse (88% of reported cases of severe anaphylaxis). | An estimated 1.24% to 16.8% of the population of the United States is considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens, especially [[penicillin]] and insect stings. Most of these people successfully avoid their [[allergen]]s and will never experience anaphylaxis. Of those people who actually experience anaphylaxis, up to 1% may die as a result.<ref>Neugut, Alfred, Anita Ghatak and Rachel Miller. "Anaphylaxis in the United States: An Investigation Into Its Epidemiology." Arch Intern Med. 161.108 January 2001 15-21. 29 January 2007 <http://archinte.ama-assn.org/cgi/content/full/161/1/15>.</ref> Anaphylaxis results in fewer than 1,000 deaths per year in the U.S. (compared to 2.4 million deaths from all causes each year in the U.S.<ref name="urlFASTSTATS - Deaths and Mortality">{{cite web |url=http://www.cdc.gov/nchs/fastats/deaths.htm |title=FASTSTATS - Deaths and Mortality |format= |work= |accessdate=2013-02-13}}</ref>). The most common presentation includes sudden cardiovascular collapse (88% of reported cases of severe anaphylaxis). | ||
===Developing Countries=== | |||
==References== | ==References== | ||
Revision as of 15:40, 12 April 2021
|
Anaphylaxis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Anaphylaxis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Anaphylaxis epidemiology and demographics |
|
Risk calculators and risk factors for Anaphylaxis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Dushka Riaz, MD
Epidemiology and Demographics
Incidence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
Prevalence
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Case-fatality rate/Mortality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
- Patients of all age groups may develop [disease name].
- The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
- [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Developed Countries
An estimated 1.24% to 16.8% of the population of the United States is considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens, especially penicillin and insect stings. Most of these people successfully avoid their allergens and will never experience anaphylaxis. Of those people who actually experience anaphylaxis, up to 1% may die as a result.[1] Anaphylaxis results in fewer than 1,000 deaths per year in the U.S. (compared to 2.4 million deaths from all causes each year in the U.S.[2]). The most common presentation includes sudden cardiovascular collapse (88% of reported cases of severe anaphylaxis).
Developing Countries
References
- ↑ Neugut, Alfred, Anita Ghatak and Rachel Miller. "Anaphylaxis in the United States: An Investigation Into Its Epidemiology." Arch Intern Med. 161.108 January 2001 15-21. 29 January 2007 <http://archinte.ama-assn.org/cgi/content/full/161/1/15>.
- ↑ "FASTSTATS - Deaths and Mortality". Retrieved 2013-02-13.